Welcome to LookChem.com Sign In|Join Free

CAS

  • or

210240-75-8

Post Buying Request

210240-75-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

210240-75-8 Usage

General Description

Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C10H22N2O2. It is an ester derivative of carbamic acid and is also known as tert-butyl (3-aminopentyl)carbamate. Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI) is commonly used in organic synthesis and pharmaceutical research. It is a colorless liquid with a faint odor and is soluble in organic solvents. It is important to handle this chemical with care and follow proper safety precautions when working with it.

Check Digit Verification of cas no

The CAS Registry Mumber 210240-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,0,2,4 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 210240-75:
(8*2)+(7*1)+(6*0)+(5*2)+(4*4)+(3*0)+(2*7)+(1*5)=68
68 % 10 = 8
So 210240-75-8 is a valid CAS Registry Number.

210240-75-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-(3-aminopentyl)carbamate,hydrochloride

1.2 Other means of identification

Product number -
Other names W4395

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:210240-75-8 SDS

210240-75-8Downstream Products

210240-75-8Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

Terzi?, Natasa,Konstantinovi?, Jelena,Tot, Miklo?,Burojevi?, Jovana,Djurkovi?-Djakovi?, Olgica,Srbljanovi?, Jelena,?tajner, Tijana,Verbi?, Tatjana,Zlatovi?, Mario,Machado, Marta,Albuquerque, Inês S.,Prudêncio, Miguel,Sciotti, Richard J.,Pecic, Stevan,D'Alessandro, Sarah,Taramelli, Donatella,?olaja, Bogdan A.

supporting information, p. 264 - 281 (2016/01/29)

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

ACYCLIC 1,3-DIAMINES AND USES THEREFOR

-

Page/Page column 116-117, (2010/10/20)

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted -acyclic diamines according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein: the R groups are as defined herein. The present invention also relates to a pharmaceutical composition and a method of treatment using the compound of Formula (I).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 210240-75-8